Abstract
Objective: The primary objective of this study is to determine whether proper (FDA-labelled) use of alvimopan for patients with a gynecologic malignancy who undergo bowel surgery affects hospital length of stay. We also sought to understand whether alvimopan use is associated with return to bowel function defined as time to flatus, time to bowel movement, and time to tolerance of regular diet × 24 hours.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
